DBS Safe But Not Beneficial in Parkinson's Dementia
TUESDAY, Dec. 19, 2017 -- Low-frequency deep brain stimulation of the nucleus basalis of Meynert (NBM DBS) can be safely conducted in patients with Parkinson's disease dementia, but it does not result in significant improvements in primary cognitive outcomes, according to a study published online Dec. 18 in JAMA Neurology.
James Gratwicke, M.D., Ph.D., from University College London, and colleagues evaluated six patients with Parkinson's disease dementia who were treated with NBM DBS. After surgery, patients received either active stimulation (bilateral, low-frequency [20 Hz] NBM DBS) or sham stimulation for six weeks followed by the opposite condition for the next six weeks.
The researchers found that all patients tolerated surgery and stimulation well with no reports of serious adverse events. There were no consistent improvements in primary cognitive outcomes or in resting state functional magnetic resonance imaging results. NBM DBS patients saw an improvement in Neuropsychiatric Inventory scores versus sham stimulation (8.5 versus 12 points).
"Low-frequency NBM DBS was safely conducted in patients with Parkinson disease dementia; however, no improvements were observed in the primary cognitive outcomes," the authors write. "Further studies may be warranted to explore its potential to improve troublesome neuropsychiatric symptoms."
Several authors disclosed financial ties to the pharmaceutical and medical device industries.
© 2020 HealthDay. All rights reserved.
Posted: December 2017
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.